FDA Tightens Rules on Compounded Obesity Drugs and Appoints New Biologics Director

FDA Proposes Restricting Compounded Versions of Popular Obesity and Diabetes Drugs

The U.S. Food and Drug Administration (FDA) has taken a significant step that could reshape access to widely used weight loss and diabetes medications. The agency proposed removing the active ingredients in Novo Nordisk's Wegovy and Ozempic, as well as Eli Lilly's Mounjaro and Zepbound, from a list of substances that large compounding facilities can use to produce mass quantities of drugs. The decision, announced recently, centers on semaglutide and tirzepatide—the key components driving the obesity and diabetes treatment market.

According to a report by STAT, the FDA determined there is no “clinical need” for large-scale compounding of these medications. This ruling marks a victory for Novo Nordisk and Eli Lilly, who have faced increasing competition from compounding pharmacies that offer cheaper, unapproved versions of their blockbuster drugs. The agency explained that these compounders no longer meet the legal requirements to market their products, effectively tightening the regulatory framework around off-patent replicas.

What This Means for Consumers

The decision directly affects patients who have relied on compounded versions of semaglutide and tirzepatide due to lower costs or supply shortages. While the FDA’s move aims to ensure safety and efficacy, it may limit options for those struggling with obesity or diabetes who cannot afford brand-name drugs. Consumer advocates have raised concerns about accessibility, but the agency maintains that the risks of unregulated compounding—such as contamination or incorrect dosing—outweigh the benefits.

For a deeper dive into the controversy surrounding compounded weight loss drugs, check out our analysis of the compounding industry's role.

FDA Names New Acting Director for Biologics Center Amid Leadership Turmoil

In a separate but equally significant development, the FDA announced that Katherine Szarama has been appointed as the acting director of the Center for Biologics Evaluation and Research (CBER). This regulatory arm oversees vaccines, gene therapies, and the nation’s blood supply. Szarama replaces Vinay Prasad, who left the agency on Thursday after a tumultuous tenure marked by controversial decisions on rare disease drugs and vaccine approvals.

FDA Commissioner Marty Makary stated in March that Prasad would return to the University of California, San Francisco, where he previously served as a professor. Szarama joined the FDA at the end of last year to serve as Prasad’s deputy, and her interim appointment raises questions about the long-term direction of CBER. Government and industry sources have indicated that Houman Hemmati, an ophthalmologist, biopharma executive, and frequent Fox News contributor, was a top candidate for the permanent role.

Implications for Vaccine and Gene Therapy Regulation

The leadership change comes at a critical time for CBER, which is navigating post-pandemic vaccine oversight and the rapid advancement of gene therapies. Stakeholders are watching closely to see whether Szarama will continue Prasad’s policies or chart a new course. The FDA has not confirmed whether Szarama will serve permanently, leaving the door open for further shifts in regulatory philosophy.

To understand the impact of leadership changes on drug approvals, see our section on regulatory trends.

The Compounding Debate: Balancing Access and Safety

The FDA’s proposal on semaglutide and tirzepatide is the latest chapter in a long-running debate over compounding pharmacies. These facilities produce customized or bulk versions of drugs that are not commercially available, often at lower prices. However, they have faced scrutiny for manufacturing unauthorized copies of popular medications, especially during shortages. The agency’s decision highlights the tension between patient affordability and regulatory oversight.

Large compounders, known as 503B facilities, had argued that their products fill a crucial gap for patients unable to afford brand-name drugs. But the FDA countered that the active ingredients in question are readily available from the original manufacturers, undermining the legal justification for compounding. This ruling could set a precedent for other high-demand drugs, potentially limiting the compounding industry’s growth.

Navigating a Shifting Regulatory Landscape

Both stories—the FDA’s compounding restrictions and the CBER leadership change—reflect a broader evolution in pharmaceutical regulation. As weight loss drugs become blockbusters and biologic therapies advance, the FDA faces pressure to balance innovation, safety, and access. The agency’s actions suggest a tightening of controls on off-patent copies while signaling potential shifts in how it evaluates cutting-edge treatments.

For pharmaceutical companies and patients alike, staying informed about these regulatory moves is essential. The FDA’s decisions will influence drug pricing, availability, and the pace of medical breakthroughs in the years to come.

This article is based on reporting from STAT and other public sources. For more details on the FDA’s compounding list and CBER leadership, refer to the original STAT article.